Numerous studies have analyzed R&D productivity and measured drug approval rates, but an analysis focused on success rates has limitations, providing only one piece to the puzzle.

Presentation will cover four key strategic questions that each biopharmaceutical company should be able to answer prior to launching a new product, outline the types of analyses required to address those questions and provide examples of the insights that these tools have generated.